Regeneron Pharmaceuticals, Inc. (REGN) — Free Cash Flow Yield
Healthcare
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
| Metric | Value |
|---|---|
| FCF Yield | 4.5% |
| Healthcare Sector Avg FCF Yield | 4.9% |
| Annual Free Cash Flow | $3.8B |
| Market Cap | $82.7B |
| P/E Ratio | 19.9x |
Regeneron Pharmaceuticals, Inc.'s FCF yield of 4.5% is below the Healthcare sector average (4.9%).
Frequently Asked Questions
What is Regeneron Pharmaceuticals, Inc.'s (REGN) free cash flow yield?
Regeneron Pharmaceuticals, Inc.'s (REGN) free cash flow yield is 4.5%. That is below the Healthcare sector average (4.9%).
Is REGN's free cash flow yield good?
At 4.5%, REGN's free cash flow yield is considered fair — yields above 10% are generally excellent, 7–10% good, 4–7% fair, and below 4% weak, though context varies by sector and growth stage.
How much free cash flow does Regeneron Pharmaceuticals, Inc. generate?
Regeneron Pharmaceuticals, Inc. generated $3.8B in free cash flow, against a market cap of $82.7B.
How is free cash flow yield calculated?
Free cash flow yield = (Free Cash Flow ÷ Market Capitalization) × 100%. Free cash flow equals operating cash flow minus capital expenditures.
Data from public filings. Not investment advice. Calculate your own FCF yield →